TB-500 Dosing Schedule: Titration, Timing, and Missed Doses

TB-500 at a glance:

• Drug class: Research peptide (not FDA-approved)
• Route: subcutaneous injection (in research)
• Typical frequency: weekly loading then maintenance protocols are described in non-clinical literature
• Half-life: approximately 2-3 hours after subcutaneous administration in animal studies

Most people who quit TB-500 do it during titration, and most of those quits trace to dosing decisions. Get the schedule right and the rest is much easier.

Standard Dosing Schedule for TB-500

No established human dosing. Veterinary use in racehorses is banned by most racing authorities.

The typical schedule for TB-500 is weekly loading then maintenance protocols are described in non-clinical literature via subcutaneous injection (in research). Half-life of approximately 2-3 hours after subcutaneous administration in animal studies explains why this schedule works — the drug stays active long enough to support that interval.

Titration: Why Starting Low Matters

For this class of compound, gradual titration is the standard approach. The starting doses listed above are not therapeutic — they exist to let the body adapt and to reduce gastrointestinal symptoms .

A typical titration plan for TB-500 holds each dose step for at least four weeks before moving up. Faster titration is associated with more dropouts due to side effects.

Missed Doses

If a dose of TB-500 is missed: for weekly schedules, the rule of thumb is to take it as soon as remembered if within a defined window, otherwise skip it and resume the regular schedule. The exact window depends on the half-life (approximately 2-3 hours after subcutaneous administration in animal studies) and the specific product label. Never double up to make up for a missed dose.

Dose Adjustments

Dose adjustments may be needed for the following:

• Significant weight loss or weight gain
• Side-effect intolerance at the current step
• Changes in renal or hepatic function
• Drug interactions (particularly relevant for any concurrent medications)

We cover the side-effect side of dose decisions in TB-500 side effects and the cost angle of dose escalation in TB-500 cost.

What the Trials Used

Published trial data for TB-500 comes primarily from: Goldstein et al. (multiple reviews) — preclinical evidence. RGN-259 (a thymosin beta-4 eye drop) has been studied for dry-eye disease.

That data drives the labeled dosing range, which is what physicians prescribe by.

Special Populations

The dosing guidance above applies to general adult use. Special populations — pregnancy, pediatric, severe renal impairment, hepatic dysfunction, elderly with frailty — require individualized assessment that this page can't substitute for.

For TB-500: the standard contraindications for this drug class apply.

Bottom Line

Dosing TB-500 is a long game. Get the titration right, hold steady, and adjust deliberately based on how your body responds.

Frequently Asked Questions

Related Reading

• TB-500: The Complete 2026 Guide (Mechanism, Dosing, Cost)
• TB-500 Side Effects Decoded: What's Normal vs. What Isn't
• What Results Should You Expect from TB-500? A Practical Guide
• The Real TB-500 Price Tag in 2026 — With and Without Insurance
• What Is BPC-157? Everything You Should Know Before Starting
• Is BPC-157 Safe? An Honest Look at the Side-Effect Profile

Sources

• Sosne G et al. Thymosin Beta 4: A Potential Novel Therapy for Neurotrophic Keratopathy. Expert Opinion 2015;15:663.
• Sikiric P et al. Stable Gastric Pentadecapeptide BPC 157 — Major Wound-Healing Properties. Pharmaceuticals 2020;13:155.
• Goldstein AL et al. Thymosin β4: A Multi-Functional Regenerative Peptide. Annals NY Acad Sci 2012;1269:1.

This page is informational only and is not medical advice. We do not provide guidance for self-administration of compounds that are not FDA-approved.